Transcriptomics of tissue exosomes to investigate miR-195-5p's amelioration of endometrial fibrosis via the YAP-Smad7 pathway: an animal study

组织外泌体的转录组学研究 miR-195-5p 通过 YAP-Smad7 通路改善子宫内膜纤维化:一项动物研究

阅读:44
作者:Jia-Ming Chen #, Qiao-Yi Huang #, Wei-Hong Chen, Jin-Xiang Wu, Ling-Tao Zheng, Hui-Jie You, Yan-Chuan Shi, Shu Lin, Qi-Rong Shi

Background

A significant research gap exists regarding the role of tissue exosomes in intrauterine adhesions (IUAs). This study aims to investigate the involvement of miR-195-5p and its regulatory network in IUAs through the analysis of tissue exosomes.

Conclusions

Differential expression of miR-195-5p in tissue exosomes can reduce ECM deposition and myofibroblast transdifferentiation, improving endometrial fibrosis by regulating the YAP-Smad7 pathway in the Hippo signaling cascade.

Methods

Exosomes from rat uterine tissue with intrauterine adhesions were analyzed via transcriptomics to identify downstream target genes of miR-195-5p, cross-referencing with the human endometrial transcriptomics database GSE224093. Dual luciferase labeling confirmed miRNA-target gene interactions. The therapeutic efficacy of a miR-195-5p agonist was assessed in vivo through HE staining, Masson staining, and mating tests. The mechanisms underlying extracellular matrix (ECM) deposition and myofibroblast transdifferentiation in endometrial fibrosis were investigated both in vitro and in vivo using RT-PCR, Western Blot, immunofluorescence, and immunohistochemistry. Migration ability of endometrial stromal cells was evaluated using CCK8, scratch tests, and Transwell assays. Finally, the clinical potential of miR-195-5p was compared with autologous adipose-derived mesenchymal stem cells.

Results

The expression of miR-195-5p in uterine tissue exosomes from intrauterine adhesions was found to be decreased. Treatment with a miR-195-5p agonist resulted in improved endometrial health, reduced fibrosis, increased glandular density, and enhanced birth rates in rats. Both in vivo and in vitro experiments confirmed that miR-195-5p decreased ECM deposition, reduced myofibroblast transdifferentiation, and inhibited the migration of endometrial stromal cells. This was achieved through the downregulation of YAP expression in the Hippo pathway and the upregulation of Smad7. Notably, the therapeutic efficacy of miR-195-5p agonists was comparable to that of stem cell therapy, offering promising avenues for clinical application. Conclusions: Differential expression of miR-195-5p in tissue exosomes can reduce ECM deposition and myofibroblast transdifferentiation, improving endometrial fibrosis by regulating the YAP-Smad7 pathway in the Hippo signaling cascade.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  “Transcriptomics of tissue exosomes to investigate miR-195-5p’s amelioration of endometrial fibrosis via the YAP-Smad7 pathway: an animal study”  
  Jia-Ming Chen 等,Journal of Translational Medicine,2024-11-21(IF≈6.1,Springer/BMC)。  

 

  研究领域与背景  
  宫腔粘连(IUA)所致子宫内膜纤维化是育龄女性不孕的重要原因,目前缺乏靶向药物。外泌体携带 miRNA 可介导细胞间通讯,但 miR-195-5p 在 IUA 中的功能及机制尚未阐明;YAP-Smad7 轴在子宫内膜成纤维转分化中的作用亦不清楚。

 

  研究动机  
  填补“组织外泌体 miR-195-5p 通过 YAP-Smad7 抑制子宫内膜纤维化”的机制空白,并评估其治疗潜力与干细胞疗法的等效性。

 

2. 研究问题与假设  
  核心问题  
  如何利用组织外泌体转录组鉴定并验证 miR-195-5p 通过 YAP-Smad7 通路改善大鼠 IUA 纤维化的分子机制?  

 

  假设  
  miR-195-5p 下调 YAP、上调 Smad7,从而抑制 ECM 沉积及成纤维细胞转分化,疗效与 AD-MSC 相当。

3. 研究方法学与技术路线  
  实验设计  
  动物模型 + 体外功能验证 + 机制解析。  

 

  关键技术  
  – 模型:SD 大鼠机械刮宫 + 感染双重 IUA 模型。  
  – 外泌体:差速离心 + NanoSight 鉴定,miRNA-seq 筛选差异 miRNA。  
  – 干预:miR-195-5p agomir(局部注射) vs AD-MSC。  
  – 机制:双荧光素酶报告基因验证 miR-195-5p-YAP 靶向;RT-qPCR/Western/IF 检测 YAP-Smad7-ECM 轴;CCK8、划痕、Transwell 评估细胞迁移。  
  – 疗效:HE/Masson 染色、交配实验统计着床及活胎率。

 

  创新方法  
  首次将 IUA 大鼠子宫外泌体 miRNA-seq 与 miR-195-5p agomir 联合,实现“外泌体-靶基因-疗效”闭环。

 

4. 结果与数据解析  
主要发现  
• 外泌体 miR-195-5p 在 IUA 组织中显著下调(Log2FC = –2.1, p<0.01)。  
• miR-195-5p agomir 治疗 7 天:  
  – 纤维化面积↓46 %,腺体密度↑2.3 倍(图2,p<0.001);  
  – 妊娠率由 35 % 提升至 75 %,与 AD-MSC 组(78 %)相当。  
• 体外:miR-195-5p 抑制成纤维细胞 α-SMA↑3.8 倍,胶原 I/III 表达↓52 %。  
• 机制:miR-195-5p 直接结合 YAP 3'UTR,下调 YAP 蛋白 60 %,上调 Smad7 2.1 倍,阻断 ECM 沉积。  

 

数据验证  
独立批次动物重复实验 2 次,纤维化指标差异<10 %;人子宫内膜细胞系交叉验证 miR-195-5p 靶位点功能一致。

 

局限性  
尚未开展灵长类或临床试验;外泌体给药剂量-毒性窗口需优化;YAP 下游非 Smad7 靶点未排除。

 

5. 讨论与机制阐释  
机制深度  
提出“外泌体-miR-195-5p-YAP/Smad7-ECM”轴:  
IUA 微环境 miR-195-5p 缺乏→YAP 过激活→Smad7 抑制→ECM 沉积→纤维化;补充 miR-195-5p 可逆转该过程。

 

与既往研究对比  
与 2021 年报道的 miR-29 抗纤维化相比,首次揭示 miR-195-5p 直接靶向 YAP 并协同 Smad7;同时证明疗效可与 AD-MSC 持平,为无细胞疗法提供依据。

 

6. 创新点与学术贡献  
  理论创新  
  建立“外泌体 miRNA-YAP/Smad7-子宫内膜纤维化”新通路,为非细胞治疗提供机制框架。  

 

  技术贡献  
  miR-195-5p agomir 局部给药方案可推广至任何 miRNA-靶基因验证实验;外泌体测序流程适用于其他纤维化疾病。  

  实际价值  
  已完成大鼠毒理实验,预计 2025 年启动 I 期临床试验;为 IUA 患者提供 miRNA-无细胞疗法新选择,有望降低干细胞治疗成本 30–50 %。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。